Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001047469-03-009104
Filing Date
2003-03-18
Accepted
2003-03-18 16:39:17
Documents
11
Period of Report
2003-05-01
Effectiveness Date
2003-03-18

Document Format Files

Seq Description Document Type Size
1 DEF 14A a2104805zdef14a.htm DEF 14A 137913
3 G325460.JPG g325460.jpg GRAPHIC 5553
4 G796760.JPG g796760.jpg GRAPHIC 3229
5 G104005.JPG g104005.jpg GRAPHIC 5519
6 G751270.JPG g751270.jpg GRAPHIC 4733
7 G975626.JPG g975626.jpg GRAPHIC 5243
8 G907212.JPG g907212.jpg GRAPHIC 6457
9 G540813.JPG g540813.jpg GRAPHIC 5593
10 G257392.JPG g257392.jpg GRAPHIC 5411
11 G480039.JPG g480039.jpg GRAPHIC 5681
12 G101737.JPG g101737.jpg GRAPHIC 37213
  Complete submission text file 0001047469-03-009104.txt   225337
Mailing Address CORNING PHARMACEUTICAL SERVICES INC 210 CARNEGIE CENTER PRINCETON NJ 08540
Business Address 210 CARNEGIE CENTER PRINCETON NJ 08540 6094524440
COVANCE INC (Filer) CIK: 0001023131 (see all company filings)

EIN.: 223265977 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-12213 | Film No.: 03607974
SIC: 8731 Services-Commercial Physical & Biological Research